Meeting
2016 ASCO Annual Meeting
Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI).
Authors
Boyu Hu
The University of Texas MD Anderson Cancer Center, Houston, TX
Boyu Hu , Hagop M. Kantarjian , Farhad Ravandi , Gautam Borthakur , Tapan M. Kadia , Alessandra Ferrajoli , William G. Wierda , Guillermo Garcia-Manero , Naval Guastad Daver , Naveen Pemmaraju , Sara Dellasala , Sherry Pierce , Elias Jabbour , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7057)
DOI
10.1200/JCO.2016.34.15_suppl.7057
Abstract #
7057
Poster Bd #
49
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
First Author: Benjamin J. Solomon
Poster
2018 ASCO Annual Meeting
Relapse prevention with second generation tyrosine kinase inhibitors for Ph+ve acute leukemia after allogenic stem cell transplantation.
First Author: Faiz K. Anwer
Poster
2014 ASCO Annual Meeting
European leukemia net (ELN) 2013 response categories: Impact on clinical outcomes across four frontline tyrosine kinase inhibitor (TKI) modalities in chronic phase CML.
First Author: Preetesh Jain
First Author: Ronald J. Rieder